Companies › Grace Science
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GS-100 Gene replacement therapy for NGLY1 deficiency delivered via intracerebroventricular admini | NGLY1 | Phase 3 | NGLY1 Deficiency | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06199531 | GS-100 | Phase 3 | NGLY1 Deficiency | Metabolic and endocrine | Mar 2027 |
Cash of $14m on 2026-06-30; operating cash outflow about $13m a year; runway about 13 months at that burn, to Jul 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Yong Zhao, MD, PhD Spur Therapeutics iECURE BioLab Holdings AB Biotics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.